List of Excipients in Branded Drug MAXALT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	MAXALT	rizatriptan benzoate	0006-0266	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme Corp	MAXALT	rizatriptan benzoate	0006-0266	FERRIC OXIDE RED
Merck Sharp & Dohme Corp	MAXALT	rizatriptan benzoate	0006-0266	LACTOSE MONOHYDRATE
Merck Sharp & Dohme Corp	MAXALT	rizatriptan benzoate	0006-0266	MAGNESIUM STEARATE
Merck Sharp & Dohme Corp	MAXALT	rizatriptan benzoate	0006-0266	STARCH, CORN

Maxalt Excipient Strategy: Commercial Opportunities for Rizatriptan Formulations

Last updated: August 9, 2026

Maxalt is the branded rizatriptan product developed by Merck for acute migraine treatment. Its commercial value now lies less in originator exclusivity and more in formulation engineering, generic differentiation, orally disintegrating tablets, excipient substitution, pediatric usability, and lifecycle products. The core Maxalt products use relatively simple excipient systems, leaving room for manufacturers to compete on taste, disintegration, stability, allergen status, packaging, and patient convenience.

What is Maxalt and which excipients does it contain?

Maxalt contains rizatriptan benzoate, equivalent to 5 mg or 10 mg of rizatriptan. It was approved by the FDA for the acute treatment of migraine attacks with or without aura in adults. Maxalt MLT is the orally disintegrating tablet version.[1,2]

Maxalt conventional tablets

The conventional tablet uses a standard direct-compression or dry-granulation excipient platform:

Component	Function
Lactose monohydrate	Diluent and tablet bulk
Microcrystalline cellulose	Filler and dry binder
Pregelatinized starch	Binder and disintegration aid
Magnesium stearate	Lubricant
Red ferric oxide	Colorant

The conventional tablets are available in 5 mg and 10 mg strengths. The 10 mg tablet is pale pink and capsule-shaped, while the 5 mg tablet has a lower drug load and corresponding color and marking differences.[1]

Maxalt MLT orally disintegrating tablets

Maxalt MLT uses a different excipient architecture designed for rapid oral dispersion:

Component	Function
Gelatin	Matrix former and structural support
Mannitol	Bulking agent, sweetener, and cooling-mouthfeel contributor
Glycine	Bulking agent and taste modifier
Aspartame	High-intensity sweetener
Peppermint flavor	Flavor masking

The tablet is designed to dissolve on the tongue without water. The formulation is packaged in a blister system that protects the fragile dosage form from moisture and mechanical damage.[2]

The MLT platform is commercially more important than the conventional tablet because the excipient system directly affects patient acceptance, sensory performance, handling, and packaging cost.

What formulation patents protect Maxalt?

Maxalt’s primary patent value was concentrated in the rizatriptan active ingredient and early product development rather than a durable, high-complexity excipient estate. The relevant patent position has largely expired, allowing generic manufacturers to market rizatriptan tablets and orally disintegrating tablets subject to FDA approval requirements.

Compound and product protection

Rizatriptan is a selective 5-HT1B/1D receptor agonist. The original U.S. patent estate covered the chemical compound and related pharmaceutical use. FDA approval of Maxalt occurred in 1998, with Maxalt MLT approved later.[1,2]

The principal commercial barriers were:

• Patent protection for rizatriptan and related compounds.
• FDA approval requirements for abbreviated new drug applications.
• Bioequivalence requirements for tablets and orally disintegrating tablets.
• Manufacturing controls for low-dose content uniformity.
• Moisture protection for the orally disintegrating presentation.
• Sensory performance requirements for a product intended to dissolve in the mouth.

The estate no longer provides the commercial protection associated with a launch-stage originator product. Current competition is based on manufacturing economics, regulatory execution, supply reliability, and dosage-form differentiation.

Formulation patent exposure

A generic applicant can face different patent considerations depending on whether it markets:

1. A conventional tablet.
2. An orally disintegrating tablet.
3. A new taste-masked formulation.
4. A modified-release or alternative-delivery product.
5. A combination product containing rizatriptan.

The original Maxalt MLT formulation does not create a permanent barrier to competing orally disintegrating rizatriptan products. A later entrant can use a different excipient combination if it demonstrates pharmaceutical equivalence or obtains approval through an appropriate regulatory pathway.

When did Maxalt lose exclusivity?

Maxalt lost meaningful market exclusivity after the expiration of the relevant rizatriptan patent and regulatory exclusivity periods. Generic rizatriptan products are now marketed in the United States, including conventional tablets and orally disintegrating tablets.[3]

Maxalt exclusivity timeline

Milestone	Approximate timing
FDA approval of Maxalt tablets	1998
FDA approval of Maxalt MLT	2001
U.S. patent and regulatory protection period	Primarily 2000s to early 2010s
Generic rizatriptan tablet entry	After relevant patent barriers expired
Generic orally disintegrating tablet competition	Following expiration of applicable product protections
Current market position	Mature, multisource generic market

The commercial implication is direct: a new product cannot rely on Maxalt’s former brand premium. It must create a differentiated proposition through excipients, dosage form, pricing, packaging, or distribution.

What is the FDA and Orange Book status of Maxalt?

The FDA approved Maxalt under NDA 020864 and Maxalt MLT under a separate NDA.[1,2] The Orange Book historically identified the approved brand products and related patent information. Current U.S. market activity is dominated by generic rizatriptan products rather than originator exclusivity.[3]

FDA pathway for generic rizatriptan

A conventional generic tablet generally relies on an ANDA and must demonstrate:

• Pharmaceutical equivalence.
• Bioequivalence.
• Compliance with current good manufacturing practice requirements.
• Stability through the proposed shelf life.
• Adequate labeling.
• Acceptable impurity and degradation profiles.

An orally disintegrating tablet requires closer control of dosage-form performance. Relevant attributes include:

• Disintegration or dispersion time.
• Drug release.
• Tablet friability.
• Moisture sensitivity.
• Packaging integrity.
• Content uniformity.
• Taste and mouthfeel, where relevant to product design.

The FDA does not require a generic to duplicate every inactive ingredient of Maxalt. It must meet applicable regulatory standards and address any safety, labeling, or bioequivalence consequences arising from excipient differences.

What excipient strategy is most attractive for generic Maxalt?

The strongest commercial strategy is to treat excipients as a platform for product differentiation rather than as simple low-cost fillers.

1. Build a lactose-free conventional tablet

Maxalt tablets contain lactose monohydrate.[1] A competing manufacturer could replace lactose with mannitol, anhydrous dibasic calcium phosphate, microcrystalline cellulose, or a co-processed excipient system.

The commercial benefits include:

• Access to patients avoiding lactose-containing products.
• A cleaner excipient profile for certain institutional buyers.
• Potential improvement in moisture stability.
• A differentiated product specification for tenders and pharmacy contracting.

The principal technical challenge is maintaining tablet hardness, disintegration, dissolution, and low-dose content uniformity after removing lactose.

2. Develop an aspartame-free orally disintegrating tablet

Maxalt MLT contains aspartame.[2] An aspartame-free product could target patients with phenylketonuria, consumers avoiding phenylalanine sources, and purchasers seeking a simpler labeling profile.

Potential sweetener systems include:

• Sucralose.
• Acesulfame potassium.
• Steviol glycosides.
• Mannitol-based flavor systems.
• Combinations of polyols and high-intensity sweeteners.

The formulation must manage bitterness from rizatriptan, the salt form, and any degradation-related taste. A sweetener substitution that improves labeling but worsens bitterness will not produce a commercially competitive product.

3. Improve taste masking

Taste is a material barrier for orally disintegrating triptan products. Rizatriptan-containing formulations can require rapid taste suppression because the tablet disperses directly in the oral cavity.

Available approaches include:

• Ion-exchange resin complexes.
• Polymer coating.
• Lipid or wax-based coating.
• Cyclodextrin complexation.
• Microencapsulation.
• pH-controlled granulation.
• Flavor layering.
• Compression of coated drug particles.

Taste masking can support a differentiated product, but it may change dissolution and bioavailability. The formulation must preserve rapid drug release after swallowing.

4. Replace gelatin

Maxalt MLT uses gelatin.[2] A gelatin-free formulation could target vegetarian, halal, kosher, and selected institutional markets.

Possible alternatives include:

• Pullulan.
• Hypromellose.
• Modified starch.
• Pectin.
• Polyvinyl alcohol.
• Other film-forming or freeze-drying matrix materials.

The commercial opportunity is clear, but gelatin substitution can affect tablet strength, mouthfeel, drying behavior, and blister handling. A gelatin-free product may need a redesigned manufacturing process rather than a simple excipient swap.

5. Improve moisture resistance and packaging

Orally disintegrating tablets are sensitive to humidity, especially when the matrix contains hygroscopic polyols or rapidly dissolving structural components. Packaging is therefore part of the excipient and commercial strategy.

Options include:

• Alu-Alu blister packaging.
• High-barrier cold-form foil.
• Desiccant-containing secondary packaging.
• Unit-dose cartons.
• Child-resistant blister systems.
• Improved peelable lidding materials.

Packaging innovation can produce measurable value by reducing breakage, preserving disintegration performance, and supporting distribution in humid climates.

What formulations are protected or commercially differentiated by excipients?

The most defensible commercial differentiation is likely to come from a formulation package combining excipient selection, manufacturing process, and packaging.

Product concept	Key excipient or process change	Commercial target
Lactose-free tablet	Mannitol, calcium phosphate, or co-processed filler	Retail generic and institutional buyers
Aspartame-free ODT	Sucralose, acesulfame potassium, or stevia system	PKU-sensitive and label-conscious patients
Gelatin-free ODT	Pullulan, hypromellose, or modified starch	Vegetarian, halal, and kosher markets
Fast-dispersing ODT	Porous matrix or optimized freeze-drying	Convenience-driven migraine patients
Taste-masked ODT	Coated or complexed rizatriptan particles	Improved adherence and tolerability
Moisture-stable ODT	Matrix and barrier-packaging redesign	Global distribution and retail supply
Pediatric-oriented product	Lower strength, palatable flavor, robust dose handling	Pediatric migraine treatment, subject to labeling

A patent application covering only a routine substitution, such as replacing lactose with mannitol, may have limited durability. Stronger protection would combine defined excipient ratios with measurable product attributes, such as disintegration time, dissolution profile, moisture content, friability, and taste-performance data.

How strong is the Maxalt patent estate today?

The Maxalt patent estate is commercially weak as an exclusivity barrier because the originator product is mature and generic competition exists. Its strongest remaining value is historical, technical, or defensive rather than exclusionary.

Patent-strength assessment

Factor	Assessment
Active-ingredient protection	Expired or no longer commercially decisive
Conventional tablet protection	Low
Original ODT protection	Low to moderate as a historical formulation reference
New excipient combinations	Potentially protectable if non-obvious and technically supported
Manufacturing process claims	Potentially valuable where they solve stability, taste, or scale problems
Packaging claims	Useful for moisture-sensitive ODT products
Method-of-use claims	Limited incremental value in a mature acute-migraine market
Freedom-to-operate risk	Primarily dependent on later third-party formulation patents

A new entrant should focus on patent claims that capture a technical result, not merely the presence of a familiar excipient.

Which companies are challenging or competing with Maxalt?

The competitive field includes generic manufacturers with rizatriptan tablets and orally disintegrating tablets, as well as branded alternatives in the triptan class.

Direct generic competition

Generic competition can arise from manufacturers with:

• Rizatriptan benzoate 5 mg tablets.
• Rizatriptan benzoate 10 mg tablets.
• Rizatriptan orally disintegrating tablets.
• Multiple pack sizes and pharmacy-distribution channels.

The main competitive variables are acquisition cost, shortage performance, wholesaler coverage, product availability, and payer contracting. Public FDA data identify approved generic applicants, but market share changes by product, channel, and period.[3]

Therapeutic substitutes

Maxalt also competes with:

• Sumatriptan.
• Zolmitriptan.
• Naratriptan.
• Eletriptan.
• Frovatriptan.
• Ubrogepant.
• Rimegepant.
• Lasmiditan.

The newer gepant and ditan products compete on positioning, contraindication profiles, tolerability, and patient segment rather than excipient similarity. Their pricing and brand strategies can limit the commercial ceiling for a differentiated rizatriptan product.

What generic entry risks exist for a new Maxalt formulation?

The principal risks are regulatory equivalence, formulation performance, and weak willingness to pay.

Regulatory risks

A reformulated product may not fit a simple ANDA if it changes:

• Active ingredient form.
• Dosage strength.
• Route of administration.
• Release characteristics.
• Labeling.
• Therapeutic indication.

A materially novel product may require a 505(b)(2) application instead. This pathway can support new dosage forms or formulation changes but generally carries higher development cost and greater clinical or bridging-data requirements than a conventional ANDA.

Technical risks

The principal technical failure modes are:

• Slow or variable dissolution.
• Excessive bitterness.
• Poor low-dose content uniformity.
• Tablet breakage during transport.
• Moisture-related degradation.
• Inadequate blister protection.
• Inconsistent mouthfeel.
• Excipient incompatibility with rizatriptan benzoate.

Commercial risks

The generic rizatriptan market is price-sensitive. A premium formulation needs a clear reason for pharmacies, payers, or patients to select it. Taste improvements alone may not justify a material price premium unless supported by strong patient preference, better adherence, or a specific underserved population.

What manufacturing and intellectual-property barriers affect Maxalt excipients?

Conventional tablets are relatively accessible to manufacturers with standard oral-solid-dose capabilities. Orally disintegrating products create higher process sensitivity.

Manufacturing barriers

Key manufacturing capabilities include:

• Low-dose blending and segregation control.
• Uniform distribution of rizatriptan benzoate.
• Controlled granule density.
• Low-force compression for rapid disintegration.
• Freeze-drying or specialized ODT processing, where used.
• High-barrier blister packaging.
• Moisture-controlled production and storage.
• Sensory testing and taste-masking validation.

A manufacturer with a conventional tablet line may not be able to replicate the commercial performance of a high-quality ODT without new equipment or process development.

IP barriers

Potential third-party patent exposure may involve:

• Taste-masked triptan particles.
• Porous orally disintegrating matrices.
• Freeze-dried dosage forms.
• Specific sweetener combinations.
• Mucoadhesive delivery systems.
• Buccal or sublingual delivery.
• Child-resistant packaging.
• Manufacturing methods for low-dose ODTs.

The primary IP opportunity is a new formulation patent supported by comparative data against a conventional rizatriptan product. Claims should link composition to an observable technical advantage.

What licensing deals and revenue opportunities exist for Maxalt excipients?

No major publicly disclosed excipient licensing transaction is central to the current Maxalt market. Commercial opportunities are more likely to arise through contract development, technology licensing, or supply agreements involving enabling technologies.

Attractive licensing targets

Potentially licensable technologies include:

• Proprietary taste-masking systems.
• Gelatin-free ODT matrices.
• Low-moisture orally disintegrating platforms.
• Co-processed excipients for direct compression.
• High-barrier unit-dose packaging.
• Pediatric-friendly flavor systems.
• Continuous manufacturing for low-dose tablets.

A platform licensor could offer a formulation package to multiple generic manufacturers, while a finished-dose company could seek exclusivity in defined territories or channels.

Revenue exposure

Maxalt itself is a mature branded product, and public disclosures do not provide a reliable current product-level revenue figure for the brand. The larger opportunity is the aggregate generic rizatriptan market, where profitability depends on volume, price erosion, manufacturing cost, and supply reliability.

The highest-value commercial segments are likely:

1. High-volume U.S. generic supply.
2. Orally disintegrating products with superior handling.
3. International markets where blister stability is a distribution constraint.
4. Products excluding lactose, aspartame, or gelatin.
5. Institutional and specialty-pharmacy contracts requiring defined excipient profiles.

How does Maxalt compare with other triptan excipient strategies?

Maxalt MLT has a conventional ODT excipient profile built around gelatin, mannitol, glycine, aspartame, and flavor. Other triptan products may use conventional tablets, capsules, nasal sprays, injectable products, or newer solid oral dosage forms.

Product type	Excipient opportunity	Competitive advantage
Rizatriptan conventional tablet	Lactose replacement, improved compression	Low-cost manufacturing
Rizatriptan ODT	Taste masking, gelatin-free matrix, moisture control	Water-free administration
Sumatriptan nasal spray	Solubilization and preservative system	Rapid non-oral delivery
Sumatriptan injection	Isotonicity and sterilization	Use when oral therapy is unsuitable
Gepant tablet or ODT	Solubility enhancement and taste masking	Non-triptan positioning
Ditan tablet	Solubility and tolerability-oriented design	Alternative mechanism and patient segment

Maxalt is best positioned for an excipient-led strategy in orally disintegrating tablets. Nasal and injectable triptan products require different formulation competencies and offer less direct transferability from Maxalt’s excipient platform.

Key Takeaways

• Maxalt contains rizatriptan benzoate and is available as conventional tablets and orally disintegrating Maxalt MLT tablets.
• Conventional Maxalt tablets use lactose monohydrate, microcrystalline cellulose, pregelatinized starch, magnesium stearate, and red ferric oxide.
• Maxalt MLT uses gelatin, mannitol, glycine, aspartame, and peppermint flavor.
• Originator patent protection is no longer the principal commercial barrier; the market is multisource and generic.
• The strongest formulation opportunities are lactose-free tablets, aspartame-free and gelatin-free ODTs, taste masking, and improved moisture-protective packaging.
• New patent value is most credible when excipient composition is tied to measurable performance improvements.
• A conventional generic can generally pursue an ANDA, while a materially altered delivery system may require a 505(b)(2) strategy.
• The commercial ceiling is constrained by generic price competition and by newer migraine therapies, including gepants.
• Licensing opportunities are most likely in taste masking, ODT processing, excipient platforms, and high-barrier packaging.

FAQs about Maxalt excipient and formulation opportunities

Can Maxalt be reformulated without lactose?

Yes. A competing rizatriptan tablet can use a lactose-free filler system if it meets applicable quality, dissolution, stability, and bioequivalence requirements.

Does Maxalt MLT contain aspartame?

Yes. The Maxalt MLT label identifies aspartame among its inactive ingredients.[2] An aspartame-free product could target patients seeking to avoid phenylalanine-containing sweeteners.

Is a gelatin-free rizatriptan ODT commercially viable?

Yes. A gelatin-free ODT could target vegetarian, halal, kosher, and selected institutional markets. The main development challenge is maintaining structural integrity, rapid dispersion, and acceptable mouthfeel.

Can a generic Maxalt manufacturer claim a premium price?

Usually only with a clear product advantage. Taste, excipient exclusion, packaging stability, pediatric usability, or supply reliability would need to support the premium against established generic alternatives.

Are biosimilar risks relevant to Maxalt?

No. Rizatriptan is a small-molecule drug, not a biologic. Biosimilar regulation does not apply. Competition proceeds through generic and other small-molecule regulatory pathways.

References

1. U.S. Food and Drug Administration. (2015). Maxalt (rizatriptan benzoate) tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (2015). Maxalt-MLT (rizatriptan benzoate) orally disintegrating tablets prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2008). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.

5. U.S. Food and Drug Administration. (2018). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.